X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
statin-intolerant patients (71) 71
index medicus (48) 48
humans (46) 46
heterozygous familial hypercholesterolemia (41) 41
monoclonal-antibody (41) 41
cardiac & cardiovascular systems (37) 37
density-lipoprotein cholesterol (35) 35
subtilisin/kexin type 9 (32) 32
hypercholesterolemia (31) 31
double-blind (27) 27
pharmacology & pharmacy (26) 26
cholesterol (25) 25
evolocumab amg 145 (24) 24
statins (24) 24
cardiovascular disease (20) 20
placebo-controlled trial (20) 20
coronary-heart-disease (19) 19
low density lipoproteins (19) 19
risk factors (19) 19
antibodies, monoclonal - therapeutic use (17) 17
randomized controlled-trial (17) 17
anticholesteremic agents - therapeutic use (16) 16
hypercholesterolemia - drug therapy (16) 16
proprotein convertase 9 - antagonists & inhibitors (16) 16
triglyceride transfer protein (16) 16
alirocumab (15) 15
cholesterol, ldl - blood (15) 15
pcsk9 (15) 15
animals (14) 14
hypolipidemic agents - therapeutic use (14) 14
cardiovascular diseases (13) 13
cardiovascular-risk patients (13) 13
lipids (13) 13
atherosclerosis (12) 12
care and treatment (12) 12
dyslipidemias - drug therapy (12) 12
evolocumab (12) 12
ldl-cholesterol (12) 12
medicine & public health (12) 12
monoclonal antibodies (12) 12
cardiology (11) 11
ldl-c (11) 11
proprotein convertase 9 (11) 11
b synthesis inhibitor (10) 10
dyslipidemia (10) 10
low density lipoprotein (10) 10
proprotein convertases - antagonists & inhibitors (10) 10
treatment outcome (10) 10
cardiovascular diseases - prevention & control (9) 9
clinical trials (9) 9
homozygous familial hypercholesterolemia (9) 9
hydroxymethylglutaryl-coa reductase inhibitors - therapeutic use (9) 9
analysis (8) 8
anticholesteremic agents - pharmacology (8) 8
endocrinology & metabolism (8) 8
lipoproteins (8) 8
mutation (8) 8
pcsk9 inhibition (8) 8
acute coronary syndromes (7) 7
antibodies, monoclonal - pharmacology (7) 7
apolipoprotein-b (7) 7
apolipoproteins (7) 7
autosomal-dominant hypercholesterolemia (7) 7
cardiovascular (7) 7
cholesterol, ldl - metabolism (7) 7
familial hypercholesterolemia (7) 7
high cardiovascular-risk (7) 7
male (7) 7
medical colleges (7) 7
patients (7) 7
pcsk9 inhibitors (7) 7
peripheral vascular disease (7) 7
type-2 diabetes-mellitus (7) 7
biomarkers - blood (6) 6
cardiovascular agents (6) 6
clinical trials as topic (6) 6
coronary heart disease (6) 6
dyslipidemias - blood (6) 6
efficacy (6) 6
female (6) 6
hyperlipidemia (6) 6
hyperlipidemias - drug therapy (6) 6
kexin (6) 6
ldl cholesterol (6) 6
lipids - blood (6) 6
lipoprotein a (6) 6
low-density-lipoprotein (6) 6
pharmacology (6) 6
reducing lipids (6) 6
serine endopeptidases (6) 6
serine-protease (6) 6
subtilisin (6) 6
9 serine-protease (5) 5
abridged index medicus (5) 5
aged (5) 5
antibodies, monoclonal, humanized - therapeutic use (5) 5
b synthesis inhibition (5) 5
cardiovascular diseases - etiology (5) 5
dyslipidemias - metabolism (5) 5
every 2 weeks (5) 5
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of the American College of Cardiology, ISSN 0735-1097, 09/2017, Volume 70, Issue 10, pp. 1290 - 1301
Journal Article
Cardiovascular drugs and therapy / sponsored by the International Society of Cardiovascular Pharmacotherapy, ISSN 0920-3206, 2016, Volume 30, Issue 5, pp. 473 - 483
Journal Article
Journal Article
Advances in Therapy, ISSN 0741-238X, 12/2011, Volume 28, Issue 12, pp. 1105 - 1113
Statins are at the forefront of strategies to manage dyslipidemia, although they are not always well tolerated. At 6–7 months after the drug was supplied,... 
policosanol | elderly patients | statin-intolerant | Rheumatology | Oncology | Internal Medicine | berberine | hypercholesterolemia, nutraceuticals | Medicine & Public Health | statins | Cardiology | Pharmacology/Toxicology | red yeast rice | Endocrinology | Berberine | Hypercholesterolemia | Red yeast rice | Statin-intolerant | Policosanol | Elderly patients | Statins | Nutraceuticals | SUPPLEMENT | MEDICINE, RESEARCH & EXPERIMENTAL | ACTIVATION | METAANALYSIS | CHOLESTEROL | INCREASES | ACUTE CORONARY SYNDROMES | COMBINATION | PHARMACOLOGY & PHARMACY | AMP-KINASE | DYSLIPIDEMIA | Single-Blind Method | Folic Acid - therapeutic use | Prospective Studies | Cholesterol - blood | Humans | Male | Biological Products - pharmacology | Fatty Alcohols - therapeutic use | Hypercholesterolemia - drug therapy | Fatty Alcohols - pharmacology | Aged, 80 and over | Ubiquinone - therapeutic use | Female | Biological Products - therapeutic use | Ubiquinone - analogs & derivatives | Xanthophylls - therapeutic use | Anticholesteremic Agents - adverse effects | Blood Glucose - drug effects | Berberine - pharmacology | Medication Adherence | Anticholesteremic Agents - therapeutic use | Anticholesteremic Agents - administration & dosage | Aged | Berberine - therapeutic use | Dietary Supplements | Lipoproteins, LDL - blood | Enzymes | Safety regulations | Low density lipoproteins | Aged patients | Patient compliance | Cholesterol | Folic acid | Functional foods | Analysis | Insulin resistance | Rice
Journal Article
PharmacoEconomics, ISSN 1170-7690, 1/2018, Volume 36, Issue 1, pp. 115 - 126
The aim of this study was to assess the budget impact of introducing the proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) alirocumab and... 
Quality of Life Research | Health Economics | Health Administration | Public Health | Pharmacoeconomics and Health Outcomes | Medicine & Public Health | UNITED-STATES | SUBTILISIN/KEXIN TYPE 9 | MONOCLONAL-ANTIBODY | RANDOMIZED CONTROLLED-TRIAL | DENSITY-LIPOPROTEIN CHOLESTEROL | REDUCING LIPIDS | HEALTH CARE SCIENCES & SERVICES | RISK PATIENTS | PHARMACOLOGY & PHARMACY | HEALTH POLICY & SERVICES | STATIN-INTOLERANT PATIENTS | SERINE-PROTEASE | ECONOMICS | CORONARY-HEART-DISEASE | Drug Costs | Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage | Atherosclerosis - drug therapy | Hyperlipoproteinemia Type II - economics | United States | Antibodies, Monoclonal - pharmacology | Humans | Risk Factors | Anticholesteremic Agents - economics | Hydroxymethylglutaryl-CoA Reductase Inhibitors - economics | Models, Economic | Atherosclerosis - economics | Proprotein Convertase 9 - antagonists & inhibitors | Antibodies, Monoclonal - administration & dosage | Anticholesteremic Agents - administration & dosage | Adult | Cholesterol, LDL - blood | Hyperlipoproteinemia Type II - drug therapy | Drug Therapy, Combination | Antibodies, Monoclonal - economics | Budgets | Anticholesteremic Agents - pharmacology | Care and treatment | Heterozygosis | Hypercholesterolemia | Cardiovascular diseases | Analysis | Heterozygosity | Health insurance | Costs | Health care policy | Cardiovascular disease | Insurance coverage | Patients | Cholesterol | Impact analysis | Studies | Census of Population | Pharmacy | Pharmacoeconomics | Adults | Endorsements | Medicaid | Statins | Pharmaceuticals | Original
Journal Article
Journal Article